Table 3.
Hazard Ratios (95% CIs) of CVD Mortalitya Associated With Circulating Levels of FABP‐4 Among Participants With Prevalent CVD
| Q1 | Q2 | Q3 | Q4 | Per Doubling | |
|---|---|---|---|---|---|
| Model 1b | (Ref.) | 1.48 (1.05–2.07) | 1.95 (1.38–2.75) | 2.63 (1.80–3.84) | 1.80 (1.47–2.20) |
| Model 2c | (Ref.) | 1.44 (1.02–2.03) | 1.75 (1.22–2.51) | 2.23 (1.47–3.37) | 1.63 (1.31–2.04) |
BP indicates blood pressure; CRP, C‐reactive protein; FABP‐4, fatty acid binding protein‐4; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; and Ref., reference.
a
Median follow‐up time=7.8 years.
b
Adjusted for age, sex, race, field center, and waist circumference.
c
Adjusted for age, sex, race, field center, waist circumference, systolic BP, antihypertensive medications, HDL, LDL, triglycerides, CRP, fasting glucose, and hypoglycemic medications.